
Mothering, Diabetes and Obesity are my specialties. Hypercaffeinated ☕️with artistic tendencies. Tweets are mine #Diabetes #Obesity #Equity #MedEd #EndObesity
Boston, MA
Joined April 2014
- Tweets5.5K
- Following745
- Followers580
- Likes10K
Samar Hafida,MD retweeted
Join us at #ADASciSessions for United in Care: Momentum in Multi-Specialty Care Management. June 21, 12:30 P.M. CT, ADA Hub, Chicago, IL. Featuring @Dr_Giullian_MD & Dr. @Samarhafida on advancing team-based care for chronic disease. Register: bit.ly/3DUDbGC @DaVitaKidney
Samar Hafida,MD retweeted
Join us at #ADASciSessions for United in Care: Momentum in Multi-Specialty Care Management. June 21, 12:30 P.M. CT, ADA Hub, Chicago, IL. Featuring @Dr_Giullian_MD & Dr. @Samarhafida on advancing team-based care for chronic disease. Register: bit.ly/3DUDbGC @DaVitaKidney
Samar Hafida,MD retweeted
Two years of empagliflozin slowed kidney disease progression and reduced cardiovascular risk. In the follow-up study to the EMPA-KIDNEY trial, empagliflozin had additional cardiorenal benefits after discontinuation. Full study results and Research Summary: nej.md/3NE3W7K

ALT The New England Journal of Medicine Long-Term Effects of Empagliflozin in CKD A Research Summary based on The EMPA-KIDNEY Collaborative Group | 10.1056/NEJMoa2409183 | Published on October 25, 2024 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
Samar Hafida,MD retweeted
As the potency of #ObesityMedicines for #WeightLoss grows, @FDA and HCPs need to refocus on the right target for #ObesityCare. It's all about health gain, not just weight loss.
conscienhealth.org/2025/02/w…
Samar Hafida,MD retweeted
Nutritional Strategies for Reducing Postprandial Glycemia
1️⃣ Premeal nutrient intake modulates postprandial glycemia by delaying gastric emptying and influencing incretin hormone secretion, which is crucial for individuals with type 2 diabetes.
2️⃣ Protein is the most potent stimulator of glucose-dependent insulin secretion, enhances GLP-1 release, and reduces insulin clearance, improving metabolic efficiency
3️⃣ Dietary fat slows gastric emptying through potent intestinal feedback mechanisms, modulates insulin response, and enhances GLP-1 secretion when combined with protein.
3️⃣ Fruits may improve glucose tolerance via the Staub-Traugott effect, while fiber delays carbohydrate absorption, reducing postprandial insulin demand.
5️⃣ Almonds, rich in MUFAs and fiber, improve insulin sensitivity, delay glucose absorption, and may stimulate early-phase insulin release via pancreatic modulation.
Strategic premeal nutrient selection is particularly important for individuals with type 2 diabetes to optimize glycemic control and metabolic outcomes.
@DrNadolsky @TheAlanAragon @DrKarlNadolsky @drmatthewnagra
Review Link: journals.viamedica.pl/clinic…
Samar Hafida,MD retweeted
Overview of thyroid hormone action in the liver.
Thyroid hormone regulates:
✔️Gluconeogenesis
✔️De novo lipogenesis
✔️Fatty acid oxidation
✔️Cholesterol metabolism
✔️Lipophagy
journals.lww.com/hepcomm/ful…
Samar Hafida,MD retweeted
Definition and diagnostic criteria of #clinical #obesity thelancet.com/journals/landi…
#FREE to read with registration (also FREE)
Samar Hafida,MD retweeted
STEP UP Trial Top-line Results for Semaglutide 7.2 mg
Novo Nordisk has shared results from the STEP UP trial evaluating semaglutide 7.2 mg for obesity treatment:
🔹Average weight loss of 20.7% with treatment adherence over 72 weeks.
🔹18.7% weight loss on average, regardless of adherence.
🔹33% of participants achieved over 25% weight loss with 7.2 mg.
These results demonstrate greater efficacy compared to semaglutide 2.4 mg (17.5% with adherence) and placebo (2.4%), with a similar safety and tolerability profile.
Additional data, including results from the STEP UP T2D trial, are expected later this year.
#ObesityManagement #STEPUP #Semaglutide #NovoNordisk
Samar Hafida,MD retweeted
This is a great article and we need to highlight this more to protect patients from potentially harmful treatment of a disease that doesn’t have comprehensive universal coverage.
Replying to @MichaelAlbertMD
Samar Hafida,MD retweeted
Over 1 billion people live with #obesity. There is an urgent need for a universal definition & diagnosis.
🆕 A @TheLancetEndo Commission introduces a new model with categories: clinical obesity (an illness) & pre-clinical obesity. This reframing identifies medically meaningful targets for prevention & treatment.
Find out more ➡️ hubs.li/Q030v_j_0
Samar Hafida,MD retweeted
The Lancet Commission on Clinical Obesity has made it official: The clinical disease of obesity is all about health. Not size, not appearance, not BMI.
HT: @FRubinoMD @DrRobertKushner @TheLancetEndo
conscienhealth.org/2025/01/l…
Samar Hafida,MD retweeted
GLP-1 based therapies led to ~30% total body lean mass loss, in a newly published meta-analysis.
This proportion is on the higher end of what might be expected with lifestyle-based weight loss.
The 30% figure aligns more closely with what is seen with bariatric surgery.
What has yet to be more fully studied is what may impact this percentage:
- Rate of weight loss
- Degree of energy or nutrient deficiency
- Extent of physical activity
- Protein intake
onlinelibrary.wiley.com/doi/…
Samar Hafida,MD retweeted
Join the Obesity Care and Weight Management Patient Engagement Training by the American Diabetes Association® on Wednesday, October 16 at 4:00 p.m. ET to learn how to address weight stigma in health care. Register now at bit.ly/3zdEqD0.
Samar Hafida,MD retweeted
In this month's issue of @CJASN -
Optimizing the timing an sequencing of kidney protective therapies in CKD
journals.lww.com/cjasn/fullt…
#kidneyGDMT #4pillarsCKD
Samar Hafida,MD retweeted
Important points made in the Obesity Medicine Association’s latest position statement on compounded GLP1s 💉:
“Compounded drugs pose a higher risk to patients than FDA-approved drugs because compounded drugs do not undergo FDA premarket review for safety, effectiveness, or quality.
“The FDA has NOT banned compounded drugs. Depending on the circumstances, compounded drugs can be made and distributed with fewer restrictions when the drug appears on FDA’s drug shortages list
“When a drug is in shortage, compounders may be able to prepare a compounded version of that drug if they meet certain requirements. Ozempic and Wegovy are both listed on FDA’s Drug Shortages list.
“When these AOM are no longer on the FDA drug shortage list, then the justification no longer exists, and (presumably), compounding pharmacies will discontinue production.
sciencedirect.com/science/ar…
Samar Hafida,MD retweeted
📉#Tirzepatide reduces the progression of #prediabetes to #Type2Diabetes by 94% compared to placebo 👀, according to SURMOUNT-1 trial results 👏
Treatment of the underlying obesity improves overall health and prevents obesity-related complications.
These data add to an ever growing list of protection against chronic disease: heart disease, liver disease, sleep apnea, diabetic kidney disease 💯
Thanks @TIME for including me
time.com/7017001/tirzepatide…
Samar Hafida,MD retweeted
Read our DIABETES & TECHNOLOGY special issue: inc 9 reviews on diabetes tech use in T1D, T2D, older adults, children, pregnancy, CFRD, CKD, hospital settings & exercise. Also including the views of people living with diabetes and an editorial by Kar & co diabetologia-journal.org/col…
Samar Hafida,MD retweeted
We’re excited to announce that we’re partnering with @AbbottNews and @FreeStyleDiabet to integrate the FreeStyle Libre 3 Plus sensor with the iLet Bionic Pancreas.
Learn more: betabionics.com/beta-bionics…
Samar Hafida,MD retweeted
ILet Bionic Pancreas from @BetaBionics will be connecting to Libre 3 Plus from @AbbottNews at the end of the year. Another option for people with #type1diabetes
We’re excited to announce that we’re partnering with @AbbottNews and @FreeStyleDiabet to integrate the FreeStyle Libre 3 Plus sensor with the iLet Bionic Pancreas.
Learn more: betabionics.com/beta-bionics…
Samar Hafida,MD retweeted
FDA cleared the Omnipod 5 for use by people aged 18 and older with type 2 diabetes, a first for any automated insulin delivery (AID) system. OP5 will be a great option for people requiring insulin to reach glycemic goals. medscape.com/viewarticle/fda…




























